How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View.

IF 4.7 3区 医学 Q1 ONCOLOGY JCO oncology practice Pub Date : 2025-02-20 DOI:10.1200/OP-24-00935
Angioletta Lasagna, Patrizia Cambieri, Fausto Baldanti, Massimo Andreoni, Francesco Perrone, Paolo Pedrazzoli, Nicola Silvestris
{"title":"How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View.","authors":"Angioletta Lasagna, Patrizia Cambieri, Fausto Baldanti, Massimo Andreoni, Francesco Perrone, Paolo Pedrazzoli, Nicola Silvestris","doi":"10.1200/OP-24-00935","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with solid tumors present a higher risk of infectious diseases with worse outcomes compared with immunocompetent patients. Prolonged treatment of prophylactic and empirically chosen antibiotics and health care-acquired infections can predispose patients with cancer to infections with antimicrobial-resistant (AMR) organisms. AMR is a global health priority and can affect patients with cancer. The outcome of patients with cancer worsens dramatically if multidrug-resistant (MDR) microorganisms cause infections. Moreover, the emergence of MDR organisms increases health care costs. Antimicrobial stewardship programs can be useful to monitor and improve the use of antibiotics in all oncological settings, including the palliative setting. Awareness of the magnitude of these issues is still low, so it is important to inform and educate oncologists. This narrative review aims to illustrate the main evidence on infections caused by AMR organisms in patients with cancer and the tools that oncologists should have to enhance their multidisciplinary management.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400935"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP-24-00935","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with solid tumors present a higher risk of infectious diseases with worse outcomes compared with immunocompetent patients. Prolonged treatment of prophylactic and empirically chosen antibiotics and health care-acquired infections can predispose patients with cancer to infections with antimicrobial-resistant (AMR) organisms. AMR is a global health priority and can affect patients with cancer. The outcome of patients with cancer worsens dramatically if multidrug-resistant (MDR) microorganisms cause infections. Moreover, the emergence of MDR organisms increases health care costs. Antimicrobial stewardship programs can be useful to monitor and improve the use of antibiotics in all oncological settings, including the palliative setting. Awareness of the magnitude of these issues is still low, so it is important to inform and educate oncologists. This narrative review aims to illustrate the main evidence on infections caused by AMR organisms in patients with cancer and the tools that oncologists should have to enhance their multidisciplinary management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.40
自引率
7.50%
发文量
518
期刊最新文献
Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis. Engage: A Survivorship Program to Improve Childhood Cancer Survivors' Self-Efficacy and Quality of Life. Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. Health Information Disparities Among Asian American People With Cancer. How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1